Relative Effectiveness of Schizophrenia Therapy Study

Completed

Conditions studied: Schizophrenia, Bipolar Disorder

In brief

The purpose of this study is to validate that SULT4A1-1 status stratification improves responses to atypical antipsychotics in schizophrenia and to extend these findings into bipolar disorder.

Key facts

Study ID

NCT01245348

Run by

Medco Health Solutions, Inc.

People needed

1110

Starts

2010-12-01

Expected to finish

2012-12-01

Last updated by the study team

2013-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects ≥ 18 years of age
• Subjects with either a confirmed diagnosis of schizophrenia or bipolar disorder or subjects with self reported schizophrenia or bipolar disorder
• Subjects who were/are new to therapy for olanzapine, risperidone, quetiapine or ziprasidone
• Subjects who are willing and able to provide informed consent

You may not qualify if…

• Subjects initially prescribed less than the generally accepted minimally effective dose of the drugs under study
• Subjects with Major Depressive Disorder (MDD) or another psychotic disorder other than schizophrenia or bipolar disorder
• Subjects with catatonic schizophrenia
• Subjects with moderate to severe mental retardation
• Subjects that refuse to participate in the study

Where it is running

• Medco Health Solutions, Inc. — Franklin Lakes, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.